Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression
Inflammopharmacology · 2024
DOI: 10.1007/s10787-024-01565-1 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammopharmacology, 2024. Verfasst von Parviz Soufivand und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. Hauptthemen laut MEDLINE: Neuropilin-1, Forkhead Transcription Factors, Arthritis, Rheumatoid, Semaphorin-3A. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Deputy for Research and Technology, Kermanshah University of Medical Sciences.
Abstract (Originalsprache)
BACKGROUND: Semaphorins are axonal guidance molecules involved in neural development and contribute to the regulation of various phases of the immune response. This study aimed to investigate the plasma levels of the pro-inflammatory cytokine interleukin-6 (IL-6) and the regulatory T (Treg) cell-related cytokine interleukin-10 (IL-10), as well as the gene expression levels of forkhead box P3 (FoxP3), Semaphorin-3A (Sema-3A), Neuropilin-1 (Nrp-1), Semaphorin-4A (Sema-4A), and Plexin-D1 (Plxn-D1), in the peripheral blood of newly diagnosed rheumatoid arthritis (RA) patients treated with conventional disease-modifying antirheumatic drugs (DMARDs) for 6 months compared with healthy controls. METHODS: Peripheral blood samples were obtained from 40 newly diagnosed RA patients (before and after treatment) and 40 age- and sex-matched healthy subjects. The plasma concentrations of IL-6 and IL-10 were quantified via enzyme-linked immunosorbent assay (ELISA), and the mRNA expression levels of FoxP3, Sema-3A, Nrp-1, Sema-4A, and Plxn-D1 were assessed via quantitative real-time PCR. RESULTS: Compared with those in the controls, the plasma IL-6 levels in the RA patients (both pre- and post-treatment) were significantly greater (P < 0.001). Compared with the pre-treatment levels, the plasma IL-6 levels decreased significantly after DMARD therapy (P < 0.05). Moreover, plasma IL-10 levels were significantly greater in post-treatment RA patients than in controls (P < 0.05). The gene expression of FoxP3, Sema-3A, and Nrp-1 was significantly lower in pre-treated RA patients than in controls (P < 0.001). Compared with that in pre-treatment RA patients, the gene expression of FoxP3, Sema-3A, and Nrp-1 in DMARDs-treated RA patients was strongly increased (P < 0.05, P < 0.01, and P < 0.01, respectively). There was a positive correlation between Sema-3A gene expression and the gene expression of FoxP3 (r = 0.292, P < 0.01) and Nrp-1 (r = 0.569, P < 0.0001). CONCLUSION: Conventional DMARDs therapy effectively reduces disease activity and inflammation in newly diagnosed RA patients by increasing FoxP3, Sema-3A, and Nrp-1 gene expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran.
- Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. askar.roghani@gmail.com.
- Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. askar.roghani@gmail.com.
- Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, PO-Box: 6617713446, Tehran, Iran. ramin.lotfi1370@gmail.com.
Förderung
- Deputy for Research and Technology, Kermanshah University of Medical Sciences
Zitieren
APA
Soufivand, P., Hosseini Torshizi, G., Roghani, S. A., Dastbaz, M., Lotfi, R., Soleymani, B., Heydarpour, F., Abdan, Z., & Allahyari, H. (2024). Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression. Inflammopharmacology. https://doi.org/10.1007/s10787-024-01565-1
Vancouver
Soufivand P, Hosseini Torshizi G, Roghani SA, Dastbaz M, Lotfi R, Soleymani B, et al. Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression. Inflammopharmacology. 2024. doi:10.1007/s10787-024-01565-1
BibTeX
@article{Soufivand2024,
author = {Soufivand, Parviz and Hosseini Torshizi, Ghazal and Roghani, Seyed Askar and Dastbaz, Mohammad and Lotfi, Ramin and Soleymani, Bijan and Heydarpour, Fatemeh and Abdan, Zahra and Allahyari, Hosna},
title = {Conventional DMARDs therapy decreases disease activity and inflammation in newly diagnosed patients with rheumatoid arthritis by increasing FoxP3, Sema-3A, and Nrp-1 gene expression},
journal = {Inflammopharmacology},
year = {2024},
doi = {10.1007/s10787-024-01565-1}
}
EUVIMED